[1] ALIBHAI SM, LEACH M, MINDEN MD, et al. Outcomes and quality of care in acute myeloid leukemia over 40 years[J]. Cancer, 2009, 115(13): 2903. doi: 10.1002/cncr.24373
[2] CALIGIURI MA, STROUT MP, LAWRENCE D, et al. Rearrangement of ALL1(MLL) in acute myeloid leukemia with normal cytogenetics[J]. Cancer Res, 1998, 58(1): 55.
[3] DOHNER K, SCHLENK RF, HABDABK M, et al. Mutant nucleophosmin(NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations[J]. Blood, 2005, 106(12): 3740. doi: 10.1182/blood-2005-05-2164
[4] FALINI B, MECUCCI C, TIACCI E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype[J]. N Eng J Med, 2005, 352(3): 254. doi: 10.1056/NEJMoa041974
[5] WHITMAN SP, RUPPERT AS, MARCUCCI G, et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a cancer and leukemia group B study[J]. Blood, 2007, 109(12): 5164. doi: 10.1182/blood-2007-01-069831
[6] CAMPO E, SWERDLOE SH, HARRIS NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications[J]. Blood, 2011, 117(19): 5019.
[7] OKUDA T, DEURSEN J, HIEBERT SW, et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis[J]. Cell, 1996, 84(2): 321. doi: 10.1016/S0092-8674(00)80986-1
[8] ROUMIER C, ECLACHE V, IMBERT M, et al. M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hématologie Cellulaire(GFHC) and the Groupe Francais de Cytogénétique Hématologique(GFCH)[J]. Blood, 2003, 101(4): 1277. doi: 10.1182/blood-2002-05-1474
[9] KUO MC, LIANG DC, HUANG CF, et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation[J]. Leukemia, 2009, 23(8): 1426. doi: 10.1038/leu.2009.48
[10] MENDLER JH, MAHARRY K, RADMACHER MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures[J]. J Clin Oncol, 2012, 30(25): 3109. doi: 10.1200/JCO.2011.40.6652
[11] ICHIKAWA M, YOSHIMI A, NAKAGAWA M, et al. A role for RUNX1 in hematopoiesis and myeloid leukemia[J]. Int J hematol, 2013, 97(6): 726.
[12] SOOD R, KAMIKUBO Y, LIU P. Role of RUNX1 in hematological malignancies[J]. Blood, 2017, 129(15): 2070. doi: 10.1182/blood-2016-10-687830
[13] COHEN-SOLAL KA, BOREGOWDA RK, LASFAR A. RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression[J]. Mol Cancer, 2015, 14: 137. doi: 10.1186/s12943-015-0404-3
[14] CHUANG LS, ITO Y. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors[J]. Oncogene, 2010, 29(18): 2605. doi: 10.1038/onc.2010.88
[15] GOYAMA S, SCHIBLER J, CUNNINGHAM L, et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells[J]. J Clin Invest, 2013, 123(9): 3876. doi: 10.1172/JCI68557
[16] CALVANESE V, NGUYEN AT, BOLAN TJ, et al. MLLT3 governs human haematopoietic stem-cell self-renewal and engraftment[J]. Nature, 2019, 576(7786): 281. doi: 10.1038/s41586-019-1790-2
[17] WANG CL, DING BJ, JIANG L, et al. Increased expression of amyloid precursor protein promotes proliferation and migration of AML1/ETO-positive leukemia cells and be inhibited by panobinostat[J]. Neoplasma, 2015, 62(6): 864. doi: 10.4149/neo_2015_105
[18] FU Y, XU M, CUI Z, et al. Genome-wide identification of FHL1 as a powerful prognostic candidate and potential therapeutic target in acute myeloid leukaemia[J]. EBioMedicine, 2020, 52: 102664.